Targeting the shallow binding surfaces of Src Homology 2 (SH2) domains represents a significant challenge and opportunity in therapeutic development, particularly for cancer and neurodegenerative diseases.
The Signal Transducer and Activator of Transcription (STAT) proteins are critical transcription factors whose dysregulation drives numerous diseases, particularly cancer.
This article provides researchers, scientists, and drug development professionals with a comprehensive framework for understanding, performing, and troubleshooting STAT protein dimerization assays in cellular systems.
This article provides a comprehensive guide for researchers and drug development professionals on optimizing SH2 domain structural models to improve the success rate of virtual screening.
This article provides a comprehensive analysis of the strategies and challenges in achieving high selectivity between the SH2 domains of STAT and Src-family kinases (SFKs), a critical goal for developing...
The development of high-affinity inhibitors targeting the STAT-SH2 domain represents a formidable challenge in drug discovery, primarily due to the conserved nature of the phosphotyrosine-binding pocket and the poor pharmacokinetic...
This article explores the cutting-edge strategy of using intracellularly expressed SH2-binding proteins as targeted tools to disrupt phosphotyrosine signaling networks.
This article provides a comprehensive resource for researchers and drug development professionals on the phylogenetic analysis and classification of Src Homology 2 (SH2) domains.
This article provides a comprehensive resource for researchers and drug development professionals on employing molecular docking to target the phosphotyrosine (pY) and pY+3 pockets of STAT SH2 domains.
This article provides a comprehensive guide for researchers and drug development professionals on utilizing competitive binding assays to screen for inhibitors targeting the Src Homology 2 (SH2) domains of STAT...